Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLaura L. Fernandes

Discussion

Loading...

Member takes

Overview

Observational study finds poor progression-free survival in patients with TP53 mutation MDS, suggesting urgent need for improved therapies.

Key Points

  • Long-term outcomes for patients with TP53 mutation significantly worse than those without; median overall survival was only 11.8 months.
  • In the cohort of MDS patients, 22.3% with TP53 mutation progressed to acute myeloid leukemia compared to 11.9% without.
  • Analysis of treatment patterns revealed that TP53 mutation patients initiated antineoplastic therapy faster than their wild type counterparts.
  • Study highlights urgent need for further research on effective treatment strategies for high-risk TP53 mutation MDS patients.

Cite This Study

Laura L. Fernandes (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3a2https://doi.org/10.1182/blood-2025-4606
View Full Paper
Ask AI
Bookmark
Share